BeOne Medicines (BEIGF) EPS (Diluted) Growth (1y) (2017 - 2026)
Powered by 
Analysis
BeOne Medicines (BEIGF) EPS (Diluted) Growth (1y) (2017 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Diluted) Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 646.62 Bn | 625.86 Bn | 17.26 Bn | -0.91% |
| 2 | AbbVie | 442.20 Bn | 435.63 Bn | 12.70 Bn | 284.27% |
| 3 | Merck | 366.42 Bn | 359.28 Bn | 12.21 Bn | -130.72% |
| 4 | Novartis Ag | 266.80 Bn | 259.11 Bn | 11.24 Bn | -15.92% |
| 5 | Pfizer | 159.12 Bn | 147.42 Bn | 10.94 Bn | -108.14% |
| 6 | Sanofi | 52.46 Bn | 45.08 Bn | 10.79 Bn | -91.06% |
| 7 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - | - |
| 8 | Incyte | 25.39 Bn | 20.85 Bn | 1.57 Bn | 38.02% |
| 9 | United Therapeutics | 21.45 Bn | 18.78 Bn | 683.80 Mn | 13.47% |
| 10 | BeOne Medicines | 2.48 Bn | -2.62 Bn | 1.53 Bn | 144.25% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 144.25% |
| Mar 31, 2026 | 17,091.12% |
| Dec 31, 2025 | 140.64% |
| Sep 30, 2025 | 195.14% |
| Jun 30, 2025 | 172.86% |
| Mar 31, 2025 | 100.47% |
| Dec 31, 2024 | 59.03% |
| Sep 30, 2024 | -156.89% |
| Jun 30, 2024 | 68.43% |
| Mar 31, 2024 | 27.99% |
| Dec 31, 2023 | 18.46% |
| Sep 30, 2023 | 137.38% |
| Jun 30, 2023 | 33.81% |
| Mar 31, 2023 | 21.25% |
| Dec 31, 2022 | 32.17% |
| Sep 30, 2022 | -14.08% |
| Jun 30, 2022 | -5.23% |
| Mar 31, 2022 | -717.86% |
| Dec 31, 2021 | -6.13% |
| Sep 30, 2021 | 2.16% |